Daily Roundup

LIN.ASX NHC.ASX 360.ASX FBR.ASX NEU.ASX

Lindian-RA Acquires Operating MREC Facility

Lindian Resources Ltd has executed a binding term sheet to acquire 100% of an existing Mixed Rare Earths Carbonate (MREC) Processing Facility in Kazakhstan. This strategic move transforms Lindian's business from concentrate-only production to high-value MREC production, attracting premium payabilities and significantly enhancing the company's economics.

The Lindian-RA joint venture will acquire 100% ownership of the Summit Atom Rare Earth Company Arctic LLP (SARECO) MREC Processing Facility and associated infrastructure. The Kangankunde Rare Earths Project and SARECO MREC Facility are expected to be fully operational within approximately 9 months, with Lindian supplying around 12,500 tonnes per annum of high-quality Monazite Concentrate from Stage 1 of Kangankunde to the downstream Lindian-RA joint venture.

The acquisition represents a fraction of the estimated $500 million capital cost to construct a new MREC facility, positioning Lindian to capture downstream margins, broaden its customer base, and strengthen its negotiating position across offtake, separation, and strategic partnership discussions.

New Hope Corporation Extends On-Market Share Buy-Back

New Hope Corporation Ltd has announced an extension of its existing on-market share buy-back program to March 2027. This ongoing capital management strategy is designed to enhance shareholder value through the active management of the company's capital base.

The continuation of the buy-back is subject to prevailing share price and market conditions, and New Hope reserves the right to suspend or terminate the program at any time. Consistent with regulatory requirements, the company will immediately cancel any shares acquired under the buy-back.

Life360 Investor Presentation Highlights Growth

Life360's investor presentation showcases the company's impressive global scale, with 95.8 million monthly active users across 180+ countries and 16% U.S. smartphone penetration. The company reported strong financial performance in FY'25, with revenue of $489.5 million and an Adjusted EBITDA margin of 19%.

In addition to its core location sharing, family messaging, and driving safety features, Life360 is expanding into the pet space with the launch of a Pet GPS device and a Pet Finder Network. The presentation outlines the company's large addressable market opportunities in subscription services, advertising, item tracking, and pet tracking, as well as potential future expansion into adjacent markets like family financial services and elderly monitoring.

Life360 Reports Record Q4 2025 Results

Life360 reported record-breaking results for the fourth quarter and full year 2025. The company's monthly active users reached approximately 95.8 million, up 20% year-over-year, and it added a record 576,000 paying circles, reaching a total of 2.8 million.

For the full year, Life360 achieved 32% year-over-year revenue growth to $489.5 million and 105% growth in Adjusted EBITDA. Looking ahead to 2026, the company expects revenue growth acceleration driven by both its core subscription business and the scaling of its advertising platform, while remaining committed to balancing growth investment with margin expansion.

FBR secures binding WaaS Offtake Agreement

FBR Ltd has secured a binding Wall as a Service® (WaaS®) Offtake Agreement with Victorian-based modular building company AMOVEO. Under the agreement, AMOVEO is committed to purchasing a minimum of 5,400 vertical square metres of wall construction from FBR over a 24-month term, worth between $400,000 and $450,000.

In addition, FBR has signed a strategic Memorandum of Understanding with AMOVEO and national builder ASD Corporation Australia to jointly develop and deliver a hybrid robotic-modular construction solution across Australia. The partnership aims to integrate FBR's Hadrian robotic blocklaying technology with AMOVEO's factory-built modular prefabricated service cores, addressing housing supply constraints and the affordable housing shortage.

Acadia to request CHMP re-examination for trofinetide

Neuren Pharmaceuticals' partner, Acadia Pharmaceuticals, plans to request a re-examination of the European Medicines Agency's CHMP opinion that recommended refusal of marketing authorization for trofinetide to treat Rett syndrome. Trofinetide is already approved in the United States, Canada, and Israel, representing the first and only treatment approved for Rett syndrome.

Neuren's CEO expressed full support for Acadia's plan to re-examine the CHMP opinion, noting the unmet medical need in Europe remains substantial and urgent. While the pivotal LAVENDER clinical trial successfully met its co-primary and key secondary endpoints, the CHMP cited perceived deficits, including the limited magnitude of the treatment effect and the influence of patient discontinuations on the assessment of longer-term outcomes.